Image-Guided Minimally Invasive Spinal Decompression (IG-MILD / mild®) for Spinal Stenosis
Customize your policy alerts
Sign up for all Blue Cross Blue Shield - Rhode Island policy alerts
Know when Blue Cross Blue Shield - Rhode Island releases new policies or updates existing guidance.
Monitor payer policy activity
This policy governs coverage and coding for percutaneous image-guided minimally invasive lumbar decompression (IG-MILD / mild®) for spinal stenosis for Blue Cross Blue Shield - Rhode Island members, distinguishing Medicare Advantage and Commercial product positions.
No material clinical or coverage changes in this revision.
Coverage Determinations
inv-01: Medicare Advantage — Covered only in CMS-approved CED trial
Covered when ALL of the following are met:
Claims must be billed with appropriate clinical trial modifiers (Q0 for investigational services or Q1 for routine clinical services); Medicare claims filed without the Q0 modifier will deny as not medically necessary.
inv-02: Commercial Products — Not medically necessary
Covered when ALL of the following are met:
Rationale: evidence is insufficient to determine an improvement in net health outcome; available trials have limitations including lack of blinding, variable comparators, and short follow-up.
inv-03: Medicare Advantage (study) and Commercial product stance
Coverage stance varies by product and study context:
Claims for CMS-approved clinical study services must be billed with appropriate modifier(s); omission of Q0 for investigational services will result in denial as not medically necessary.
inv-04: Commercial Products — Not Medically Necessary
The percutaneous image-guided minimally invasive spinal decompression procedure (IG-MILD / mild®) is indicated for treatment of central lumbar spinal stenosis only. The devices and technique are not intended for disc procedures and are not to be used near lateral neural elements. The procedure targets resection of hypertrophied ligamentum flavum and small laminar bone fragments under fluoroscopic guidance to decompress the central canal; it cannot address nerve root compression or disc herniation requiring treatment.
G0276 (blinded procedure for lumbar stenosis, percutaneous image-guided lumbar decompression or placebo-control performed in an approved CED clinical trial) is not medically necessary for Commercial Products.
For members covered under Commercial Products, IG-MILD/PILD is considered not medically necessary because the available evidence is insufficient to demonstrate an improvement in net health outcome. Randomized trials have limitations (including lack of blinding, variable comparators, and short follow-up), and the current literature does not adequately establish efficacy compared with placebo, open decompression, or consistent conservative management.
The specific service identified by HCPCS code G0276 is classified as not medically necessary for Commercial members and therefore is not covered under Commercial Products.
Procedure Codes and Modifiers
| G0276 | Blinded procedure for lumbar stenosis, percutaneous image-guided lumbar decompression (PILD) or placebo-control, performed in an approved coverage with evidence development (CED) clinical trial |
| Q0 | Investigational clinical service provided in a clinical research study that is in an approved research study (modifier) |
| Q1 | Routine clinical service provided in a clinical research study that is in an approved clinical research study (modifier) |
| G0276 | Blinded procedure for lumbar stenosis, percutaneous image-guided lumbar decompression (PILD) or placebo-control, performed in an approved coverage with evidence development (CED) clinical trial |
| Q0 | Investigational clinical service provided in a clinical research study that is in an approved research study (modifier) |
| Q1 | Routine clinical service provided in a clinical research study that is in an approved clinical research study (modifier) |
What Providers Must Do / Watch For
Prior authorization: Not applicable
Prior authorization is not required for this service.
Follow Clinical Trials Medicare Advantage Plans billing/coding procedures
When treating Medicare Advantage members in a CMS‑approved CED trial, follow the Clinical Trials Medicare Advantage Plans billing/coding procedures and apply the appropriate clinical‑trial modifier (Q0 for investigational services, Q1 for routine clinical services).
Billing guidance: use required Q0/Q1 modifiers for CED claims
Bill G0276 only with the required clinical‑trial modifier(s) for Medicare CED claims: Q0 for investigational clinical services or Q1 for routine clinical services as specified by Clinical Trials Medicare Advantage Plans guidance.
- Include Modifier Q0 for investigational clinical service provided in an approved research study.
- Include Modifier Q1 for routine clinical service provided in an approved clinical research study.
Clinical trial billing: include appropriate trial modifier
If treating a Medicare Advantage member as part of a CMS‑approved study, follow the policy procedures for correct billing and coding of clinical trial services and include the appropriate modifier (Q0 or Q1).
Follow Clinical Trials Medicare Advantage Plans procedures
When providing services to Medicare Advantage members enrolled in a CMS‑approved study, follow the Clinical Trials Medicare Advantage Plans procedures for correct billing and coding and bill with the appropriate modifier (Q0 for investigational clinical service, Q1 for routine clinical service).
Denial risk if Q0 modifier omitted on Medicare claims
Medicare claims for study services filed without modifier Q0 will deny as not medically necessary.
- Ensure investigational services in an approved research study are billed with Modifier Q0 to avoid denial.
Medicare Advantage denial risk for missing Q0 modifier
Medicare Advantage claims for study services submitted without the Q0 modifier (investigational clinical service) will deny as not medically necessary; bill investigational study procedures with Q0 to prevent denial.
Clinical Background
Lumbar spinal stenosis involves narrowing of the spinal canal that can produce neurogenic claudication, typically characterized by leg pain, numbness, or weakness that worsens with standing or walking and is relieved by sitting. Conventional posterior decompression (eg, laminectomy, laminotomy) is established therapy; the IG-MILD procedure is an ultra–minimally invasive, percutaneous, fluoroscopically guided decompression that specifically targets ligamentum flavum hypertrophy to decompress the central canal but does not treat lateral neural element pathology or disc herniation.
Definitions and Terms
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.